Clinicaltrial Invest Information

Pharmaceuticals
SciSparc Granted FDA Approval for Phase IIb Trial of Novel Tourette Syndrome Therapy Oct 1, 2024
Pharmaceuticals
Novartis's Kisqali Demonstrates a 28.5% Decrease in Recurrence Risk in Early Breast Cancer Patients Sep 17, 2024
Pharmaceuticals
SciSparc Ltd. (NASDAQ:SPRC) Soars on Positive Clinical Trial Launch Nov 25, 2023